AbbVie Inc (BUE:ABBV)
ARS 21100 275 (1.32%) Market Cap: 326.28 Til Enterprise Value: 391.76 Til PE Ratio: 63.33 PB Ratio: 53.42 GF Score: 74/100

AbbVie Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2024 / 01:00PM GMT
Release Date Price: ARS12411.5
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Good morning, and welcome to Day 3 of the Barclays Global Healthcare Conference. We're in the home stretch here. My name is Carter Gould. I cover U.S. BioPharma. I'm very pleased to welcome AbbVie to the stage. We have a full house here incoming CEO, Rob Michael, is here; as well as Scott, Jeff and Roopal across finance, commercial and development. Thank you all for joining us.

Robert A. Michael
AbbVie Inc. - President & COO

Thank you for having us.

Questions & Answers

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Plenty to dig into here. AbbVie was one of our top picks for the year. So we're absolutely excited to have you guys on stage. Maybe Rob to start historically, AbbVie, I think, has been characterized as under investing in R&D, at least as relative to its sales. We've talked in pretty forceful language around how that's changed more recently. I think one of the questions is that now as you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot